RxDoctor Payments Data

Melody Eide, MD

Dermatology · Rapid City, SDNPI 1942419759

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 77.2% of it on its own, with 9 other manufacturers making up the rest.

$2,074in general payments, 2019–2025

Across 89 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$120
  • Sanofi$96
  • Regeneron Healthcare Solutions, Inc.$72
  • E.r. Squibb & Sons, L.L.C.$65
  • Galderma Laboratories, L.p.$47
  • plus $73 from 4 others

What the payments were for

  • Food & beverage$2,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,074 in reported general payments places this provider in the 65th percentile of 44 dermatology providers in South Dakota.

See all dermatology providers in South Dakota

Medicare billing

Part B allowed, 2024
$334,060
Medicare patients
762
Services billed
6,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast17$90,999
Fluorouracil55$3,224
Imiquimod147$3,078
Tacrolimus16$1,751
Metronidazole29$1,587
Fluocinolone Acetonide16$1,300
Tretinoin15$1,210
Ketoconazole53$1,117
Clobetasol Propionate22$905
Doxycycline Hyclate20$694
Triamcinolone Acetonide120$662
Clindamycin Phosphate16$558
Mupirocin60$535
ValacyclovirValacyclovir Hcl44$434
Hydrocortisone75$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$22$90,99917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 44 dermatology providers in South Dakota.

Other dermatology in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →